Dupilumab (Dupixent)
Canadian Journal of Health Technologies · 02.07.2026 · 6 (7)
DOI: 10.51731/cjht.2026.1469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 02.07.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dupilumab (Dupixent), 300 mg single-use syringe or pen (300 mg/2 mL), solution for subcutaneous injection. Indication: Add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
Zitieren
APA
CDA-AMC (2026). Dupilumab (Dupixent). Canadian Journal of Health Technologies, 6(7). https://doi.org/10.51731/cjht.2026.1469
Vancouver
CDA-AMC. Dupilumab (Dupixent). Canadian Journal of Health Technologies. 2026;6(7). doi:10.51731/cjht.2026.1469
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Dupilumab (Dupixent)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {7},
doi = {10.51731/cjht.2026.1469}
}
EUVIMED